SecBot SecBot
DEF 14A ·Filed Nov 10, 2026

CPHI

CHINA PHARMA HOLDINGS, INC.
BEARISH
Impact 5/10
Horizonweeks Processed6d 23h ago SEC0001213900-26-118012
Definitive proxy statement
Actionable Insight ▼ Bearish

Monitor the December 22 vote outcome on the reverse split and the massive equity plan expansion. If approved, the 14x increase in authorized shares for compensation creates substantial future dilution risk. The reverse split, if executed at a ratio above 1:20 before April 2027, could trigger immediate delisting procedures under NYSE American rules if the company later fails the low price test.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$0.5431
T+0 close · Nov 10, 2026 · via day close
Latest settled
+3.09%
T+1 · $0.5599
Vs SPY
+3.45%
α at T+1
Next horizon
T+5
in 15h
  1. T+0 · Nov 11 $0.5431entry
  2. T+1 · 5d ago +3.09%α +3.45% · $0.5599
  3. T+4 · todayOpen
  4. T+5 · in 15h Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

China Pharma Holdings filed its definitive proxy statement for the December 22, 2026 annual meeting. The meeting agenda includes the election of three independent directors, authorization of a reverse stock split of up to 1:50 to maintain NYSE American listing compliance, and a massive 14-fold increase in the share reserve under the 2010 Long-Term Incentive Plan from 569,600 to 8,603,800 shares. The company also discloses material related-party loans from Chairperson Zhilin Li totaling $1.78 million and a $1.88 million compensation payable balance.

Key Facts

  • CEO/Chair Zhilin Li received $316,000 total compensation in FY2025, unchanged from FY2024.
  • Board seeks authorization for a reverse stock split of up to 1:50 to address NYSE American low selling price compliance; a 1:10 reverse split was already completed on April 15, 2025.
  • Proposal 3 seeks to increase the share reserve under the 2010 Long-Term Incentive Plan by 8,034,200 shares (from 569,600 to 8,603,800 shares), a roughly 14x increase.
  • As of the record date, only 9,800 shares of restricted stock/options were outstanding and 559,800 shares remained available under the plan.
  • Related-party loans from Chairperson Li total $1,784,671 outstanding, plus $237,408 in interest-free demand borrowings.
  • Executive compensation payable to Chairperson Li was $1,883,506 as of June 30, 2026.
  • The company has a market cap of $25M and a 30-day volatility of 51.4%.
  • No Say-on-Pay vote or shareholder proposals are on the ballot.
  • All three independent director nominees (Bennett, Zhang, Dong) are incumbents, ages 78, 81, and 85 respectively.

Financial Impact

The proposed 8,034,200 share increase under the incentive plan represents approximately 18.7% of the 43,022,002 shares outstanding as of the record date, valued at roughly $4.5 million at the $0.565 closing price on November 9, 2026. Related-party debt to the Chairperson totals $1,784,671 plus $237,408 in demand borrowings.

dilutiondebtexecutive compensation

Risk Factors

  • Massive 14x increase in share reserve for incentive compensation creates significant dilution risk for existing shareholders.
  • Reverse stock split may not maintain NYSE American listing compliance; a ratio above 1:20 before April 2027 could trigger immediate delisting without cure period under new exchange rules.
  • Heavy reliance on related-party loans from the Chairperson ($1.78M outstanding) indicates potential liquidity constraints.
  • Executive compensation payable to the Chairperson ($1.88M) is very large relative to the $25M market cap.
  • All three independent director nominees are over 78 years old with long tenures since 2008, raising governance concerns about board refreshment.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEF 14A Filing (Primary)0001213900-26-118012
Document: 0001213900-26-118012-index-headers.html0001213900-26-118012
Document: 0001213900-26-118012-index.html0001213900-26-118012
Document: 0001213900-26-118012.txt0001213900-26-118012

Track record

4 reports on CPHI

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 17, 2026today NT 10-Q Bearish 6/10 Entry $0.4800 Now $0.5000 −4.17% settles Nov 18
  2. Nov 10, 20266d ago DEF 14A Bearish 5/10 Viewing Entry $0.5431 to $0.5599 Now $0.5000 +7.94% ▼ −3.09% −3.45% vs SPY
  3. Jul 23, 202616w ago 424B5 Bearish 6/10 Entry $1.85 to $1.52 Now $0.5000 +72.97% ▲ +17.84% +17.94% vs SPY
  4. Jul 22, 202616w ago 8-K Neutral 4/10 Entry $1.85 to $1.52 Now $0.5000 −72.97% ▼ −17.84% −17.94% vs SPY
Showing 4 of 4

US Market Status

Market Closed · Opens Wed (17h 28m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026